

Southwest Nebraska Public Health Department

**Weekly Briefing
November 3, 2021**



Nebraska Plains
Healthcare
Coalition

Heidi Wheeler

Statewide COVID 19 Overview

Emergency Response Coordinator Update

erc@swhealth.ne.gov

- ❖ Decrease of 56 case (-18, -27,- 9, +18,-21)
- ❖ Total positive cases 413(357, 375, 402, 411, 385)
- ❖ 7-day positivity rate 9.9% (9.3, 10.1,10.5 9.0,8.8, 9, 8.7, 8.6, 7.1, 8.6, 7.7)
- ❖ Average of 51 new covid patients admitted per day (40, 44,46,47, 46, 39)
- ❖ 14-day average of 10.5% of staffed hospital beds occupied by Covid Pts (9.1, 9.7, 10.3, 10.6,10.0, 10.5, 9.2, 8.8)
- ❖ 31% of hospitalized COVID patients are in ICU (33, 32, 30, 28, 32, 29,27)
- ❖ 50% of COVID ICU Patients are on Vents (50, 46, 57, 57, 54, 57, 54, 49, 47)
- ❖ 25% of statewide ICU patients are COVID patients (23, 24,26, 23, 26, 21,)
- ❖ 19 Pediatric Admits last week (15, 7, 11, 14, 11)
- ❖ Case Counts in LTCF
 - ❖ 232 total staff (111)
 - ❖ 220 Total Residents (152)
 - ❖ 126 Facilities reporting outbreaks

Dr. Ashraf recommends that residents In LTCF who are eligible get the booster dose!

New confirmed cases of Covid-19 in Nebraska and Colorado

Seven-day rolling average of new cases (per 100k)



© Financial Times analysis of data from the Johns Hopkins CSSE.
Data updated November 1 2021 6.11pm GMT. Interactive version: ft.com/covid19

FINANCIAL TIMES

New confirmed cases of Covid-19 in Nebraska, Colorado, Wyoming, Montana and Idaho

Seven-day rolling average of new cases (per 100k)



©

Source: Financial Times analysis of data from the Johns Hopkins CSSE.
Data updated November 1 2021 6.11pm GMT. Interactive version: [ft.com/covid19](https://www.ft.com/covid19)

FINANCIAL TIMES

New confirmed cases of Covid-19 in Nebraska, Colorado, Kansas, North Dakota and South Dakota

Seven-day rolling average of new cases (per 100k)




© f

Source: Financial Times analysis of data from the Johns Hopkins CSSE.
Data updated November 1 2021 6.11pm GMT. Interactive version: ft.com/covid19


FINANCIAL TIMES

Proportion of Cases by Age Group

Proportion of new COVID-19 cases by age group, by week of specimen collection date, last 90 days



Proportion of new COVID-19 cases by age group, by week of specimen collection date, since 4/1/2020



- Age Group**
- 0-4
 - 5-17
 - 18-29
 - 30-49
 - 50-64
 - 65-74
 - 75+

Data Source: COVID-19 Lab ODS, Nebraska Electronic Disease Surveillance System (NEDSS)


Breakdown of age groups

October 26-November 1

Total 101

<u>Age Group</u>	<u># of Cases</u>
0-19	24
20-29	10
30-39	6
40-49	11
50-59	10
60-69	23
70-79	12
80+	5

SWNPHD COVID-19 Cases by Month



**Vaccination rates for residents of the health district
have reached**

52.2%

(+.7% from last week) (+13.2% from July 1, 2021)

Total residents of the health district vaccinated

19,961

(+272 from last week)

**COVID-19
Vaccination
Program Manager
Update**

to request vaccine supply:
nurse@swhealth.ne.gov

Pfizer-BioNTech COVID-19 Vaccines

PRELIMINARY – SUBJECT TO CHANGE PENDING REGULATORY GUIDANCE AND AUTHORIZATION/APPROVAL

Description	Current Adult/Adolescent Formulation (1170 and 450 packs)	Future Pediatric Formulation
	<i>Dilute Prior to Use</i>	<i>Dilute Prior to Use</i>
Age Group	12 years and older	5 to <12 years**
Vial Cap Color	PURPLE 	ORANGE 
Dose	30 mcg	10 mcg
Injection Volume	0.3 mL	0.2 mL
Fill Volume (before dilution)	0.45 mL	1.3 mL
Amount of Diluent* Needed per Vial	1.8 mL	1.3 mL
Doses per Vial	6 doses per vial (after dilution)	10 doses per vial (after dilution)
Storage Conditions		
ULT Freezer (-90°C to -60°C)	9 months	6 months
Freezer (-25°C to -15°C)	2 weeks	N/A
Refrigerator (2°C to 8°C)	1 month	10 weeks

Q: Can the current adult/adolescent formulation (purple cap) be used to vaccinate children 5 to <12 years old once the vaccine is authorized for this age group?

A: No. For children under 12 years of age, you cannot use the current formulation and will need to use the future pediatric (orange cap) formulation.

Purple Cap – Adult/Adolescent: Authorized only for aged 12 years and older



Orange Cap – Pediatric: Future authorization for aged 5- to 12 years. A separate vaccine formulation specific for a 10mcg dose will be introduced.



NOTE: Use of the current adult/adolescent formulation (purple cap) to prepare doses for children 5 to <12 years would result in an injection volume for the 10mcg dose of 0.1mL, which is both generally considered too small for typical IM injections and has not been studied.

*Diluent: 0.9% sterile Sodium Chloride Injection, USP (non-bacteriostatic; DO NOT USE OTHER DILUENTS)

**The vaccine is currently under emergency use authorization review by the Food and Drug Administration (FDA) for children 5 to <12 years old

Heterologous (mix-and-match) booster dose

- Heterologous dosing may be considered for the **booster dose** only
 - Primary series doses and additional dose should utilize the same vaccine product with limited exceptions
 - Additional dose only indicated for moderately to severely immunocompromised people who received 2 doses of mRNA vaccine
- Interval from the primary series should follow the interval recommended by the primary series
 - People who received a single dose Janssen primary series can receive a mRNA COVID-19 booster dose at least 2 months after completing primary series
- Individual risk-benefit assessment may inform which booster product to use
 - Availability of booster product
 - Risk profile of vaccine boosters, including rare events



Moderately and severely immunocompromised people

- Active treatment for solid tumor and hematologic malignancies
- Receipt of solid-organ transplant and taking immunosuppressive therapy
- Receipt of CAR-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
- Moderate or severe primary immunodeficiency (e.g., DiGeorge, Wiskott-Aldrich syndromes)
- Advanced or untreated HIV infection
- Active treatment with high-dose corticosteroids (i.e., ≥ 20 mg prednisone or equivalent per day), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, TNF blockers, and other biologic agents that are immunosuppressive or immunomodulatory

Color Coded System

▶ Moderna 1st
or 2nd Dose

Moderna
Booster

Pfizer 12+
(1st, 2nd,
booster)

Janssen (J&J)
Initial and
Booster Dose

Pfizer PEDIATRIC
(5-11)

Eligibility

Pfizer standard - 1st or 2nd Dose

Age 12+

21 days after their 1st dose (___/___/___ or before)

Pfizer standard - Booster Dose

Age 18+

Primary series Pfizer or Moderna:

6 months since 2nd dose (___/___/___ or before)

AND one of the following:

- Age 65+
- **OR** works in an occupation that has increased risk of COVID-19 transmission
- **OR** has an underlying medical condition

Primary series J&J:

2 months since initial dose (___/___/___ or before)

Pfizer **PEDIATRIC**

Age 5-11

Age key

Today's date in the year indicated, or before

Age 5-11: 2016-2010

Age 12: 2009

Age 18: 2003

Age 19: 2002

Age 65: 1956

Age 18 and younger MUST have a parent/guardian present.

Eligibility Continued

Moderna – 1st or 2nd dose

Age 18+

28 days after their 1st dose (___/___/___ or before)

Moderna- Booster Dose

Age 18+

Primary series Pfizer or Moderna:

6 months since 2nd dose (___/___/___ or before)

AND one of the following:

- Age 65+
- **OR** works in an occupation that has increased risk of COVID-19 transmission
- **OR** has an underlying medical condition

Primary series J&J:

2 months since initial dose (___/___/___ or before)

Johnson & Johnson- 1st Dose

Age 18+

Johnson & Johnson- Booster Dose

Age 18+

Primary series Pfizer or Moderna:

6 months since 2nd dose (___/___/___ or before)

AND one of the following:

- Age 65+
- **OR** works in an occupation that has increased risk of COVID-19 transmission
- **OR** has an underlying medical condition

Primary series J&J:

2 months since initial dose (___/___/___ or before)

Eligibility Continued

Vaccine Eligibility Birthdates

- **Pfizer**-Regular dose
 - Born on or before
____ / ____ / ____
- **Pfizer**-Booster dose
 - Born on or before
____ / ____ / ____
- **Pfizer**-Pediatric dose (5 to 11 yrs)
 - Born on or before
____ / ____ / ____
- **Moderna**- Regular dose
 - Born on or before
____ / ____ / ____
- **Moderna**-Booster dose
 - Born on or before
____ / ____ / ____
- **Janssen**- Regular dose and booster dose
 - Born on or before
____ / ____ / ____



[COVID-19: Click Here For Important Information & Updates](#)

Important Information on COVID-19

Anyone age 12 and older is eligible to receive COVID vaccine in Nebraska.

[COVID Vaccine Information](#)

[COVID-19 Vaccine Consent Form for Minors](#) for parents and guardians

Update: Multiple cases of the Delta variant have been confirmed in the health district.

[Information on Variants of the Virus that Causes COVID-19](#)

SWNPHD continues to recommend that residents avoid close contact and crowded or closed spaces.
Practice good health habits and monitor public health information for changes in the situation.



[Weekly Briefing on COVID in Southwest Nebraska - Powerpoint Slides](#)

[CDC Guidelines for Fully Vaccinated Individuals](#)



Beginning in November
Briefings will be
EVERY OTHER WEEK

Briefings will stay on
Wednesdays at 2PM CST
NOVEMBER DATES:
11/3, 11/17
DECEMBER DATES:
12/1, 12/15, 12/29



Questions
Comments
Concerns

Contact Information

308-345-4223

info@swhealth.ne.gov

swhealth.ne.gov